Hemab Therapeutics (NASDAQ:COAG) Stock Price Up 10.5% – Here’s What Happened

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) shares were up 10.5% during trading on Friday . The company traded as high as $30.63 and last traded at $30.63. 23,297 shares traded hands during trading, a decline of 91% from the average session volume of 253,068 shares. The stock had previously closed at $27.72.

Wall Street Analyst Weigh In

COAG has been the subject of a number of research analyst reports. Evercore started coverage on Hemab Therapeutics in a research report on Tuesday, May 26th. They issued an “outperform” rating and a $50.00 target price for the company. Wedbush assumed coverage on Hemab Therapeutics in a research note on Tuesday, May 26th. They issued an “outperform” rating and a $42.00 price objective for the company. The Goldman Sachs Group began coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They set a “buy” rating and a $36.00 target price on the stock. Wall Street Zen upgraded shares of Hemab Therapeutics to a “hold” rating in a research report on Saturday, May 9th. Finally, HC Wainwright initiated coverage on shares of Hemab Therapeutics in a research report on Wednesday, June 17th. They set a “buy” rating and a $40.00 price objective on the stock. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $41.40.

Hemab Therapeutics Trading Up 14.9%

Hemab Therapeutics (NASDAQ:COAG) last released its earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

Insider Transactions at Hemab Therapeutics

In other Hemab Therapeutics news, Director Ra Capital Management, L.P. bought 2,675,000 shares of the business’s stock in a transaction on Monday, May 4th. The stock was bought at an average price of $18.00 per share, for a total transaction of $48,150,000.00. Following the completion of the transaction, the director owned 6,149,096 shares in the company, valued at approximately $110,683,728. The trade was a 77.00% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have bought a total of 2,970,541 shares of company stock worth $55,459,603 in the last ninety days.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.